Hepatitis/MASH

Pan-virals show potential to work across all HCV genotypes.

Injection drug use most frequently linked to a positive hepatitis C screening.

Chronic hepatitis C infection linked to the prevalence of plaque and noncalcified plaque in the arteries.

Targeted drug delivery focuses on diseased cells to minimize side effects on normal cells.

Expansion addresses patients co-infected with HIV, patients with advanced cirrhosis, and patients with post-liver transplant HCV recurrence.

The FDA is considering expanding the use for a drug currently indicated as a chronic hepatitis C (HCV) treatment.

Ex-vivo lung perfusion keeps the lung alive, breathing outside the body and supported by a supply of blood and nutrients.

Hepatitis C infections are more likely to become persistent and to lead to progressive liver disease in patients with HIV.

Hepatic inflammation and metabolic factors associated with hepatosteatosis in patients with chronic hepatitis C infection.

Velpatasvir is a pangenotypic NS5A inhibitor for patients with hepatitis C genotypes 1 through 6 of the virus.

For patients with hepatitis C seeking modern treatment options, many health plans force health care professionals use criteria that are clinically unsound.

Investigators question if hepatitis A virus originated in animals.

Hepatitis C incidence rate among HIV-positive men who have sex with men grew three-fold from 1991 to 2010.

Drug that targets interaction with RNA does not damage other proteins.

An OTC drug used to alleviate allergy symptoms could treat hepatitis C virus infection as well.

An investigational combination of 3 interferon-free drugs has proven effective at treating hepatitis C virus.

Although hepatitis C virus medications are often costly to many patients, recent study results suggest that treating the disease can reduce absenteeism and increase productivity.

Concerns raised over treatment that fights fungal infections in lung transplant patients.

Improvements can be made to provide procedure-specific national benchmarks for postsurgical outcomes.

Pharmacists are ideally situated to help patients beat hepatitis C.

Entecavir treats chronic hepatitis B infection in adults with evidence of active viral replication.

Access to high cost curative antiviral HCV drugs remains a challenge for patients.

Findings may better predict organ rejection before transplantation.

An HCV infection may cause more than just liver damage.

Research may lead to a gel that instantly destroys viral particles.

Research could aid drug discovery.